120 related articles for article (PubMed ID: 10629882)
1. [The role of tachykinin NK-1 receptors in emetic action in the area postrema of ferrets].
Saito R; Ariumi H; Kubota H; Nago S; Honda K; Takano Y; Kamiya H
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():209P-214P. PubMed ID: 10629882
[TBL] [Abstract][Full Text] [Related]
2. Anti-emetic effects of a novel NK-1 receptor antagonist HSP-117 in ferrets.
Saito R; Suehiro Y; Ariumi H; Migita K; Hori N; Hashiguchi T; Sakai M; Saeki M; Takano Y; Kamiya H
Neurosci Lett; 1998 Oct; 254(3):169-72. PubMed ID: 10214984
[TBL] [Abstract][Full Text] [Related]
3. The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis.
Ariumi H; Saito R; Nago S; Hyakusoku M; Takano Y; Kamiya H
Neurosci Lett; 2000 Jun; 286(2):123-6. PubMed ID: 10825652
[TBL] [Abstract][Full Text] [Related]
4. The anti-emetic action of the neurokinin(1) receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog.
Andrews PL; Kovacs M; Watson JW
Neurosci Lett; 2001 Nov; 314(1-2):102-4. PubMed ID: 11698156
[TBL] [Abstract][Full Text] [Related]
5. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.
Watson JW; Gonsalves SF; Fossa AA; McLean S; Seeger T; Obach S; Andrews PL
Br J Pharmacol; 1995 May; 115(1):84-94. PubMed ID: 7544198
[TBL] [Abstract][Full Text] [Related]
6. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
7. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets.
Gonsalves S; Watson J; Ashton C
Eur J Pharmacol; 1996 Jun; 305(1-3):181-5. PubMed ID: 8813551
[TBL] [Abstract][Full Text] [Related]
8. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew.
Andrews PL; Okada F; Woods AJ; Hagiwara H; Kakaimoto S; Toyoda M; Matsuki N
Br J Pharmacol; 2000 Jul; 130(6):1247-54. PubMed ID: 10903962
[TBL] [Abstract][Full Text] [Related]
9. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.
Gardner CJ; Twissell DJ; Dale TJ; Gale JD; Jordan CC; Kilpatrick GJ; Bountra C; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3158-63. PubMed ID: 8719790
[TBL] [Abstract][Full Text] [Related]
10. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
Tattersall FD; Rycroft W; Francis B; Pearce D; Merchant K; MacLeod AM; Ladduwahetty T; Keown L; Swain C; Baker R; Cascieri M; Ber E; Metzger J; MacIntyre DE; Hill RG; Hargreaves RJ
Neuropharmacology; 1996; 35(8):1121-9. PubMed ID: 9121615
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
12. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
[TBL] [Abstract][Full Text] [Related]
13. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.
Gardner CJ; Armour DR; Beattie DT; Gale JD; Hawcock AB; Kilpatrick GJ; Twissell DJ; Ward P
Regul Pept; 1996 Aug; 65(1):45-53. PubMed ID: 8876035
[TBL] [Abstract][Full Text] [Related]
14. The effect of the NK1 receptor antagonist CP-99,994 on emesis and c-fos protein induction by loperamide in the ferret.
Zaman S; Woods AJ; Watson JW; Reynolds DJ; Andrews PL
Neuropharmacology; 2000 Jan; 39(2):316-23. PubMed ID: 10670427
[TBL] [Abstract][Full Text] [Related]
15. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.
Sharkey KA; Cristino L; Oland LD; Van Sickle MD; Starowicz K; Pittman QJ; Guglielmotti V; Davison JS; Di Marzo V
Eur J Neurosci; 2007 May; 25(9):2773-82. PubMed ID: 17459108
[TBL] [Abstract][Full Text] [Related]
16. The actions of fentanyl to inhibit drug-induced emesis.
Barnes NM; Bunce KT; Naylor RJ; Rudd JA
Neuropharmacology; 1991 Oct; 30(10):1073-83. PubMed ID: 1661861
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew).
Rudd JA; Ngan MP; Wai MK
Eur J Pharmacol; 1999 Feb; 366(2-3):243-52. PubMed ID: 10082206
[TBL] [Abstract][Full Text] [Related]
18. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis.
Saito R; Takano Y; Kamiya HO
J Pharmacol Sci; 2003 Feb; 91(2):87-94. PubMed ID: 12686752
[TBL] [Abstract][Full Text] [Related]
19. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets.
Bountra C; Bunce K; Dale T; Gardner C; Jordan C; Twissell D; Ward P
Eur J Pharmacol; 1993 Nov; 249(1):R3-4. PubMed ID: 7506663
[TBL] [Abstract][Full Text] [Related]
20. The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.
Stahl SM
J Clin Psychiatry; 2003 May; 64(5):498-9. PubMed ID: 12755650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
